A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro

被引:24
|
作者
You, XD
Arrowood, MJ
Lejkowski, M
Xie, LT
Schinazi, RF
Mead, JR
机构
[1] EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322
[2] VET AFFAIRS MED CTR,GEORGIA VA RES CTR AIDS & HIV INFECT,DECATUR,GA 30033
[3] CTR DIS CONTROL & PREVENT,PUBL HLTH SERV,US DEPT HLTH & HUMAN SERV,NATL CTR INFECT DIS,ATLANTA,GA 30341
关键词
Cryptosporidium parvum; chemiluminescence immunoassay; cell culture; in vitro; drug evaluation;
D O I
10.1111/j.1574-6968.1996.tb08057.x
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A chemiluminescence immunoassay (CLIA) was developed to detect Cryptosporidium parvum growth in Madin-Darby canine kidney (MDCK) cell cultures. Optimal results were obtained when MDCK cells were plated at a density of 1 X 10(4) cells/well (96-well plate) and maintained as a. monolayer for 4 days prior to infection with 2 X 10(4) parasites/well. Two compounds (paromomycin and maduramicin) were evaluated and shown to have selective activity against C. parvum in a dose-dependent manner. There was excellent correlation between CLIA and immunofluorescence assay when assessing anti-C parvum agents in MDCK cells. CLIA offers advantages over conventional enzyme-linked immunosorbent assay and immunofluorescence assay methods in that it is more sensitive and efficient. The combination of,CLIA and MDCK culture provides an efficient tool for evaluating potential anti-cryptosporidial compounds prior to testing in animal models.
引用
收藏
页码:251 / 256
页数:6
相关论文
共 50 条
  • [21] Differential expression of Cryptosporidium parvum genes in vitro and in vivo
    Jakobi, V.
    Petry, F.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 296 : 76 - 76
  • [22] Development of an improved in vitro culture system for Cryptosporidium parvum
    Wilke, Georgia
    Funkhouser-Jones, Lisa
    Ravindran, Soumya
    Kuhlenschmidt, Mark
    Stappenbeck, Thad
    Sibley, L. David
    FASEB JOURNAL, 2017, 31
  • [23] Effects of hydrogen peroxide on in vitro infection of Cryptosporidium parvum
    Huang, KH
    Yang, SG
    Healey, MC
    PROGRESS IN NATURAL SCIENCE, 2001, 11 (12) : 946 - 951
  • [25] Efficacy of select antivirals against Cryptosporidium parvum in vitro
    Woods, KM
    Upton, SJ
    FEMS MICROBIOLOGY LETTERS, 1998, 168 (01) : 59 - 63
  • [26] Evaluation of commercial enzyme immunoassay (EIA) and immunofluorescent antibody (IFA) test kits for detection of Cryptosporidium oocysts of species other than Cryptosporidium parvum
    Graczyk, TK
    Cranfield, MR
    Fayer, R
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1996, 54 (03): : 274 - 279
  • [27] Cryptosporidium parvum
    Dumaine, Jennifer E.
    Tandel, Jayesh
    Striepen, Boris
    TRENDS IN PARASITOLOGY, 2020, 36 (05) : 485 - 486
  • [28] Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth In Vitro
    Funkhouser-Jones, Lisa J.
    Ravindran, Soumya
    Sibley, L. David
    MBIO, 2020, 11 (02):
  • [29] Evaluation of in vitro and in vivo activity of benzindazole-4,9-quinones against Cryptosporidium parvum
    Kayser, O
    Waters, WR
    Woods, KM
    Upton, SJ
    Keithly, JS
    Laatsch, H
    Kiderlen, AF
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) : 975 - 980
  • [30] In vitro evaluation of anticryptosporidial agents using MDCK cell culture and chemiluminescence immunoassay
    You, XD
    Arrowood, MJ
    Lejkowski, M
    Xie, LT
    Schinazi, RF
    Mead, JR
    JOURNAL OF EUKARYOTIC MICROBIOLOGY, 1996, 43 (05) : S87 - S87